GlobeImmune, in which Celgene (CELG) owns 16%, intends to raise up to $65M in an IPO by selling...

|About: Celgene Corporation (CELG)|By:, SA News Editor

GlobeImmune, in which Celgene (CELG) owns 16%, intends to raise up to $65M in an IPO by selling 5M shares at $11-$13 each. GlobeImmune develops treatments for cancer and infectious diseases based on its Tarmogen platform; the biotech has a partnership with Gilead as well as with Celgene.